Combination Immunotherapy with vaccines targeting a new class of cancer antigens, combined with T cell agonists and checkpoint blockers: we talked about it with Bernard A. Fox (Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon) during Melanoma and Immunotherapy Bridge 2018 (November 28th-29th).